psalexa
logo

Psoriasis Therapeutic Pipeline Analysis

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: October 2017
Report Code: LS11042
Available Format:
Pages: 301

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Molecule Type

1.3.3. Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Epidemiology

4.1.4 Diagnosis

4.1.5 Treatment

4.2 Key Drivers

4.3 Key Barriers

4.4 Psoriasis Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Psoriasis Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Phase I: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Clinical Trials

5.4.4 Clinical Results

5.4.5 Strategic Development

5.4.6 Designation

5.4.7 Grants

5.4.8 Patent

5.4.9 Technology

5.5 Pre-Clinical: Drug profiles

5.6 Discovery: Drug profiles

5.7 Unknown: Drug profiles

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Psoriasis Therapeutics Pipeline

7.2 SWOT Analysis of Psoriasis Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

PIPELINE ANALYSIS OF PSORIASIS THERAPEUTICS, BY COMPANY (2017)

DESCRIPTION OF FILED DRUG CANDIDATES

CLINICAL TRIALS OF FILED DRUG CANDIDATES

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

DESCRIPTION OF UNKNOWN DRUG CANDIDATES

COMPANIES- AT A GLANCE

 

LIST OF FIGURES

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

PATHOPHYSIOLOGY OF PSORIASIS

PSORIASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING FOR PSORIASIS THERAPEUTICS PIPELINE

SWOT ANALYSIS OF PSORIASIS THERAPEUTICS PIPELINE

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 4000
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 5000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 8000

Pre-Purchase Enquiry